WallStreetZenWallStreetZen

NASDAQ: VTVT
Vtv Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for VTVT

Based on 1 analyst offering 12 month price targets for Vtv Therapeutics Inc

Min Forecast
$36.00+134.53%
Avg Forecast
$36.00+134.53%
Max Forecast
$36.00+134.53%

Should I buy or sell VTVT stock?

Based on 1 analyst offering ratings for Vtv Therapeutics Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their VTVT stock forecasts and price targets.

VTVT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-04-09

1 of 1

Forecast return on equity

Is VTVT forecast to generate an efficient return?

Company
-132.7%
Industry
140.91%
Market
90.47%
VTVT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is VTVT forecast to generate an efficient return on assets?

Company
-32.82%
Industry
32.45%
VTVT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

VTVT earnings per share forecast

What is VTVT's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$3.57
Avg 2 year Forecast
-$3.38
Avg 3 year Forecast
-$3.34

VTVT revenue forecast

What is VTVT's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$11.6M+68,135.29%
Avg 2 year Forecast
$43.3M+254,605.88%
Avg 3 year Forecast
$84.2M+495,194.12%
VTVT's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

VTVT revenue growth forecast

How is VTVT forecast to perform vs Biotechnology companies and vs the US market?

Company
1,594.18%
Industry
56.38%
Market
9.68%
VTVT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
VTVT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

VTVT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
VTVT$15.35$36.00+134.53%Buy
KLRS$2.64N/AN/A
IPSC$0.58$3.75+552.17%Strong Buy
STTK$1.01$4.00+296.04%Buy
ARTV$1.98$17.60+788.89%Buy
View Top Biotech Stocks

Vtv Therapeutics Stock Forecast FAQ

Is Vtv Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: VTVT) stock is to Buy VTVT stock.

Out of 1 analyst, 0 (0%) are recommending VTVT as a Strong Buy, 1 (100%) are recommending VTVT as a Buy, 0 (0%) are recommending VTVT as a Hold, 0 (0%) are recommending VTVT as a Sell, and 0 (0%) are recommending VTVT as a Strong Sell.

If you're new to stock investing, here's how to buy Vtv Therapeutics stock.

What is VTVT's earnings growth forecast for 2025-2027?

(NASDAQ: VTVT) Vtv Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.

Vtv Therapeutics's earnings in 2025 is -$18,689,000.On average, 1 Wall Street analyst forecast VTVT's earnings for 2025 to be -$11,404,593, with the lowest VTVT earnings forecast at -$11,404,593, and the highest VTVT earnings forecast at -$11,404,593. On average, 1 Wall Street analyst forecast VTVT's earnings for 2026 to be -$10,797,626, with the lowest VTVT earnings forecast at -$10,797,626, and the highest VTVT earnings forecast at -$10,797,626.

In 2027, VTVT is forecast to generate -$10,669,844 in earnings, with the lowest earnings forecast at -$10,669,844 and the highest earnings forecast at -$10,669,844.

What is VTVT's revenue growth forecast for 2028-2030?

(NASDAQ: VTVT) Vtv Therapeutics's forecast annual revenue growth rate of 1,594.18% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.68%.

Vtv Therapeutics's revenue in 2025 is $17,000.On average, 1 Wall Street analysts forecast VTVT's revenue for 2028 to be $37,056,942, with the lowest VTVT revenue forecast at $37,056,942, and the highest VTVT revenue forecast at $37,056,942. On average, 1 Wall Street analysts forecast VTVT's revenue for 2029 to be $138,324,621, with the lowest VTVT revenue forecast at $138,324,621, and the highest VTVT revenue forecast at $138,324,621.

In 2030, VTVT is forecast to generate $268,982,289 in revenue, with the lowest revenue forecast at $268,982,289 and the highest revenue forecast at $268,982,289.

What is VTVT's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: VTVT) forecast ROA is -32.82%, which is lower than the forecast US Biotechnology industry average of 32.45%.

What is VTVT's Price Target?

According to 1 Wall Street analyst that have issued a 1 year VTVT price target, the average VTVT price target is $36.00, with the highest VTVT stock price forecast at $36.00 and the lowest VTVT stock price forecast at $36.00.

The Wall Street analyst predicted that Vtv Therapeutics's share price could reach $36.00 by Apr 9, 2026. The average Vtv Therapeutics stock price prediction forecasts a potential upside of 134.53% from the current VTVT share price of $15.35.

What is VTVT's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: VTVT) Vtv Therapeutics's current Earnings Per Share (EPS) is -$2.96. On average, analysts forecast that VTVT's EPS will be -$3.57 for 2025, with the lowest EPS forecast at -$3.57, and the highest EPS forecast at -$3.57. On average, analysts forecast that VTVT's EPS will be -$3.38 for 2026, with the lowest EPS forecast at -$3.38, and the highest EPS forecast at -$3.38. In 2027, VTVT's EPS is forecast to hit -$3.34 (min: -$3.34, max: -$3.34).

What is VTVT's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: VTVT) forecast ROE is -132.7%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.